Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 17/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3546873 | 0.90 | HDAC1 (0.56) | HDAC1GAAHDAC2 | |
| SCHEMBL3553156 | 0.88 | HDAC1 (0.58) | HDAC1HDAC2 | |
| SCHEMBL3548349 | 0.88 | HDAC1 (0.53) | HDAC1ALDH1A1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL3554756 | 0.86 | HDAC1 (0.58) | HDAC1HDAC2 | |
| SCHEMBL3551917 | 0.85 | HDAC2 (0.59) | HDAC1HDAC2 | |
| SCHEMBL3554815 | 0.83 | HDAC1 (0.56) | HDAC1ALDH1A1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL3558649 | 0.82 | HDAC2 (0.61) | HDAC1ALDH1A1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL3551891 | 0.82 | HDAC1 (0.55) | HDAC1ALDH1A1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL3551291 | 0.79 | HDAC2 (0.63) | HDAC1HDAC2 | |
| SCHEMBL3552655 | 0.79 | HDAC1 (0.62) | HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732475-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-06-08 | — | — | US | claimed |
| CN-101263121-A | Histone deacetylase inhibitors | TAKEDA SAN DIEGO INC (US) | 2008-09-10 | — | — | CN | claimed |
| EP-1904452-A2 | HISTONE DEACETYLASE INHIBITORS | Takeda San Diego, Inc. (US) | 2008-04-02 | — | — | EP | claimed |
| WO-2007011626-A2 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2007-01-25 | — | — | WO | claimed |
| US-20070015809-A1 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2007-01-18 | — | — | US | claimed |
| US-7741494-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-7741494-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-7741494-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-7732475-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732475-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732475-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-20090111996-A1 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2009-04-30 | — | — | US | disclosed |
| US-20080108829-A1 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2008-05-08 | — | — | US | disclosed |
| US-20080108829-A1 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2008-05-08 | — | — | US | disclosed |
| EP-1904452-A2 | HISTONE DEACETYLASE INHIBITORS | Takeda San Diego, Inc. (US) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007011626-A2 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007011626-A2 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2007-01-25 | — | — | WO | disclosed |
| US-20070015809-A1 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2007-01-18 | — | — | US | disclosed |
| US-20070015809-A1 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2007-01-18 | — | — | US | disclosed |
| US-20070015809-A1 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015809-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC3, HDAC5 | HDAC1 1/4885ALDH1A1 754/4885RAB9A 3623/4885 |
| US-20080108829-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC3, HDAC5 | HDAC1 1/4885ALDH1A1 754/4885RAB9A 3623/4885 |
| US-20090111996-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC3, HDAC5 | HDAC1 1/4885ALDH1A1 754/4885RAB9A 3623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.